Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

Fiche publication

Date publication

avril 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Saint-Ghislain M, Chabaud S, Dalenc F, Allouache D, Cameron D, Martinez M, Grenier J, Barthelemy P, Brunt M, Kaluzinski L, Mailliez A, Legouffe E, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Canon JL, Bliss J, Lemonnier J, Andre F, Bachelot T, Cottu P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40239366

Résumé

The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses.